louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05446181: CLIC1 in Patients Presenting PD
Official title: Accumulation of Chloride Intracellular Channel 1 (CLIC1) Protein in Circulating Monocyte in Elderly Patients Presenting Postoperative Delirium and Its Predictable Role of Postoperative Delirium
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hip Fractures
Hip Disease
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2022-07-06
Enrollment: 62
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing hip joint surgery are divided into the PD group or non-PD group

Brief summary: In this study, mononuclear cells, particularly monocytes, were collected from the peripheral blood of elderly patients who underwent orthopedic hip surgery under spinal anesthesia. We then observe the accumulation of chloride intracellular channel 1 (CLIC1), particularly the characteristic accumulation morphology and its function. The purpose of this study is to compare whether there is a difference in the degree and form of cytoplasmic CLIC1 accumulation between the elderly group with postoperative delirium (PD) and the elderly group without postoperative delirium. We'll also confirm whether this is appropriate as a predictor of postoperative delirium. In addition, we will establish a control group for the non-elderly group to check the difference due to aging itself.


Eligibility criteria: Inclusion Criteria:

Male or female patients aged 65 years or older who are scheduled to undergo surgery for an orthopedic hip fracture under spinal anesthesia

Exclusion Criteria:

* Patients who are unconscious
* Patients who are unable to communicate
* Alzheimer
* Parkinson Disease
* Conversion to general anesthesia

Primary outcomes:
measure: expression pattern of CLIC1 protein
timeFrame: Immediate after spinal anesthesia
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National Univ. Bundang Hospital
state: Gyeonggi
Study officials:
References:
Clinical trial NCT00190281: Contrast-Enhanced US of Spleen, Liver and Kidney
Official title: Contrast-Enhanced US of Spleen, Liver and Kidney in Patients With Acute Infection (Malaria and Other Infectious Diseases: a Functional Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Malaria
Pyelonephritis
Bacterial Infections
Keywords: FUNCTIONAL STUDY
CONTRAST-ENHANCED US
PERFUSION
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2005-09-19
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: To evaluate the changes in the microcirculation of the liver, kidney and spleen during acute infection in patients with malaria (cohorts 1 and 3) and other infectious diseases such as acute pyelonephritis at day 0 (within 8 hours of the treatment start), day 2 to 4 and day 28-32, using functional US with continuous infusion of a contrast agent (SonoVue, Bracco, Italy).

Study hypothesis: malaria patients should exhibit a different pattern of enhancement, particularly when quantitative measurements of the SU signals is performed with destruction reperfusion kinetics.

Detailed description: To evaluate the changes in the microcirculation of the liver, kidney and spleen during acute infection in patients with malaria (cohorts 1 and 3) and other infectious diseases such as acute pyelonephritis at day 0 (within 8 hours of the treatment start), day 2 to 4 and day 28-32, using functional US with continuous infusion of a contrast agent (SonoVue, Bracco, Italy).

Three cohortes will be studied: cohorte 1 infection at Plasmodium falciparum (24 patients), cohorte 3 infection at Plasmodium vivax, ovale or malariae (5 patients) and cohorte 2 other infectious diseases such as acute pyelonephritis (24 patients).

Study hypothesis: malaria patients should exhibit a different pattern of enhancement, particularly when quantitative measurements of the SU signals is performed with destruction reperfusion kinetics.

Eligibility criteria: Inclusion Criteria:

* Social security number
* Age over 18
* acute malaria infection or other infectious diseases
* Inpatients
* Signed informed consent form

Exclusion Criteria:

* Pregnancy
* Criteria of bad tolerance of infection
* Treatment started for more than 8 hours
* Lack of cooperation
* History of splenectomy, hematological disease, cirrhosis with portal hypertension, splenomegaly
* Medical treatment with beta blocker, diuretic, immunodepression drugs

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Department of Adult Radiology, Necker University Hospital
state: Ile de france
Study officials:
affiliation: NECKER UNIVERSITY HOSPITAL
name: Jean-Michel Correas, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Centre Médical - Institut Pasteur
name: Pierre Buffet, MD PhD
role: STUDY_DIRECTOR
affiliation: NECKER UNIVERSITY HOSPITAL
name: Olivier Lortholary, MD PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04268095: Post Operative Dressing After Clean Elective Hand Surgery
Official title: Post Operative Dressing After Clean Elective Hand Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Trigger Finger Disorder
Carpal Tunnel Syndrome
Ganglion
Lead sponsor: Tel Aviv Medical Center
Sponsor class: OTHER
First posted: 2020-02-13
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Very little has been published about the optimal post operative dressing protocol, and no practical conclusion has emerged from a meta-analysis published in 2013. Even fewer studies focused on that topic specifically in hand surgery. Nevertheless, the functional impairment due to a dressing in the hand is much greater than anywhere else, due to the constant use of hands in daily life activities. Yet, habits differs widely following surgeon's preference, from daily change with application of an antimicrobial unguent, to unchanged dressing until the first follow up consultation after 2 weeks, to complete removal of the dressing and basic soap and water cleaning at postoperative day (POD) 1. Those varying recommendations have functional and logistical implication for the patients, especially the elderlies, for whom autonomy is a fragile status that can be dramatically impaired by such protocols. The goal of this study is to define which post operative dressing protocol is optimal in terms of wound complications (disunion, infection)


Eligibility criteria: Inclusion Criteria:

\* Elective hand surgery with clean wound (Type 1 in wound classification of american college of surgeon 11) - (Carpal tunnel, trigger finger, cyst removal or foreign body removal, tendon release).

Exclusion Criteria:

* Insertion of hardware
* Known skin condition disturbing normal healing,
* Immunodeficiency,
* Incapacity to understand or to observe the self cleaning protocol.
* Unexpected peroperative complication leading to a modification of the operative technique.

Primary outcomes:
measure: Change in Instrumental activities of daily living questioner (IADL)
timeFrame: Baseline (Pre-op), 2 weeks, 6 weeks, 3 months
measure: Change in Vancouver Scar Scale
timeFrame: 2 weeks, 6 weeks, 3 months
measure: Change in quick Disability of the Arm, Shoulder and Hand questioner (DASH)
timeFrame: Baseline, 2 weeks, 6 weeks, 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv medical cemter
state: IL
Study officials:
References:
Clinical trial NCT02363595: Genomic Predictors of Papillary Microcarcinoma Disease Progression
Official title: Genomic Predictors of Papillary Microcarcinoma Disease Progression
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Papillary Microcarcinoma
Keywords: Genomic Predictors
14-277
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: Ohio State University
name: University of Pittsburgh
First posted: 2015-02-16
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All papillary thyroid cancer patients evaluated at MSKCC clinic.

Brief summary: The study is being done to answer the following question: What are the specific clinical and molecular features that will help us predict which small thyroid cancers are likely to grow and be problematic?

Therefore, the purpose of this study is to identify specific clinical and molecular characteristics that are predictive of tumor progression in small thyroid cancers.


Eligibility criteria: Inclusion Criteria:

* Biopsy proven papillary thyroid cancer (or suspicious for papillary thyroid cancer) confirmed by MSKCC cytopathologist.
* Being followed with active surveillance at MSKCC
* Biopsied index nodule less than or equal to 2 cm in maximum dimension
* Thyroid and neck US performed and interpreted by a MSKCC radiologist within 6 months prior to study entry.

Exclusion Criteria:

* Biopsied index nodule greater than 2 cm in any dimension
* Age less than 18 yrs old

Primary outcomes:
measure: estimate the disease progression rate
timeFrame: 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Robert Tuttle, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00759395: Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
Official title: An Investigation of the Antidepressant Efficacy of a Selective, High, Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Anxious Major Depressive Disorder
Keywords: Anxious Major Depressive Disorder
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-09-25
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.


Eligibility criteria: Inclusion Criteria:

* Provision of informed consent prior to any study specific procedures
* Diagnosis of major depressive disorder without psychotic features (MDD)

Exclusion Criteria:

* A history of substance or alcohol abuse within the past 6 months or dependence within 1 year of enrollment as defined by DSM-IV criteria.
* Women that are pregnant or lactating
* History of pancreatitis

Primary outcomes:
measure: Hamilton Rating Scale for Depression (HAM-D) Total Score.
timeFrame: Week 4
measure: Hamilton Rating Scale for Anxiety (HAM-A) Total Score.
timeFrame: Week 4
Secondary outcomes:
measure: Psychic Anxiety Item of the Hamilton Rating Scale for Depression (HAM-D).
timeFrame: Week 4
measure: The Number of Participants With at Least 50% Reduction of Hamilton Rating Scale for Depression (HAM-D)Total Score.
timeFrame: Randomization to week 4
measure: The Number of Participants With at Least 50% Reduction of Hamilton Rating Scale for Anxiety (HAM-A)Total Score.
timeFrame: Randomization to week 4
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Research Site
state: Maryland
Study officials:
affiliation: AstraZeneca
name: Mark Smith, MD
role: STUDY_DIRECTOR
affiliation: National Institute of Mental Health (NIMH)
name: Carlos Zarate
role: PRINCIPAL_INVESTIGATOR
References:
citation: Richards EM, Mathews DC, Luckenbaugh DA, Ionescu DF, Machado-Vieira R, Niciu MJ, Duncan WC, Nolan NM, Franco-Chaves JA, Hudzik T, Maciag C, Li S, Cross A, Smith MA, Zarate CA Jr. A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. Psychopharmacology (Berl). 2016 Mar;233(6):1119-30. doi: 10.1007/s00213-015-4195-4. Epub 2016 Jan 4.
Clinical trial NCT06664281: Effects of SIT Combined with Remote Ischemic Preconditioning on Vascular Function in Young Women with Masked Obesity
Official title: Effects of Sprint Interval Training Combined with Remote Ischemic Preconditioning on Vascular Function in Young Women with Masked Obesity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vascular Function
Keywords: Sprint Interval Training
Masked Obesity
Young Women
Ischemic Preconditioning
Vascular Function
Lead sponsor: Beijing Sport University
Sponsor class: OTHER
First posted: 2024-10-29
Enrollment: 44
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Comparison of the effects of combined Sprint Interval Training (SIT) with Remote Ischemic Preconditioning (RIPC) and SIT on vascular function in young women with masked obesity.

Detailed description: This is a randomized clinical trial of single-blind with 3 arms (control group, SIT group and SIT with RIPC group), in which a pre-treatment-posttest design has been used.

Eligibility criteria: Inclusion Criteria:

* Females aged between 18 and 30 years;
* BMI within the normal range (18.5～24.9 kg/m²), BF% \> 30%;
* Participants with no clinically diagnosed contraindications for exercise, in good health, and not engaged in regular exercise, as determined by the health and physical activity questionnaire (based on the American College of Sports Medicine's guidelines for exercise testing and prescription).

Exclusion Criteria:

* History of cardiovascular diseases, including coronary heart disease, stroke, or peripheral arterial disease diagnosed through vascular imaging techniques;
* Currently participating in other intervention studies, including dietary, nutritional, or psychological education programs;
* Those with regular professional training;
* Musculoskeletal disorders that make long-term exercise interventions unsuitable.

Primary outcomes:
measure: Intima-Media Thickness (IMT)
timeFrame: 8 weeks
measure: Flow-Mediated Dilation (FMD)
timeFrame: 8 weeks
Secondary outcomes:
measure: Body Composition Indicator
timeFrame: 8 weeks
measure: Human Morphometric i Indicators
timeFrame: 8 weeks
measure: Blood Pressure (BP)
timeFrame: 8 weeks
measure: Nitric Oxide (NO)
timeFrame: 8 weeks
measure: Maximum Oxygen Uptake (VO2max)
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Beijing
country: China
facility: School of Sports Medicine and Rehabilitation, Beijing Sport University
Study officials:
References:
Clinical trial NCT05672381: NIRST and ICG-based Perfusion Imaging in Acute Compartment Syndrome
Official title: Near-infrared Spectroscopic Tomography (NIRST) and ICG-based Perfusion Imaging to Diagnose and Assess Muscle Viability in High Energy Trauma At Risk for Acute Compartment Syndrome: a Pilot Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Compartment Syndromes
Compartment Syndrome of Lower Leg
Compartment Syndrome of Forearm
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
Collaborators: name: Dartmouth College
First posted: 2023-01-05
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects receiving care at DHMC (Lebanon) with high energy lower leg or forearm trauma at risk for Acute Compartment Syndrome.

Brief summary: This is a prospective observational study of patients with suspected Acute Compartment Syndrome. The primary objective of this work is to determine whether intensity changes associated with the NIRST signal, reflecting oxy- and deoxy-hemaglobin and water concentrations or ICG fluorescence signal, reflecting tissue perfusion, can be associated with development of Acute Compartment Syndrome and identification of at-risk soft tissue and muscle.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Clinical suspicion of acute compartment syndrome based on orthopaedic provider assessment. Clinical suspicion would be based upon the presence of one or more of these findings:

  * Pain out of proportion to visible findings
  * Escalating doses of pain medication
  * Pain with passive stretch of toes and/or fingers
  * Pallor, paresthesias, pulselessness
  * Tense soft tissues
  * High energy tibia or forearm fracture
* Provision of informed consent

Exclusion Criteria:

* History of allergy to ICG and/or iodine
* Pregnant women or nursing mothers
* Any patient with an open wound for whom NIRST device cannot be applied \>4cm from the open wound will be excluded from NIRST imaging.

Primary outcomes:
measure: Association of NIRST or ICG measurements with development of ACS
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
Study officials:
affiliation: Dartmouth-Hitchcock Medical Center
name: Ida L Gitajn, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06898281: Intracardiac Echocardiography-Guided Catheter Ablation for Premature Ventricular Contractions Originating From the Papillary Muscles
Official title: Effectiveness and Safety of Intracardiac Echocardiography-Guided Catheter Ablation for Premature Ventricular Contractions Originating From the Papillary Muscles: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Premature Ventricular Contractions
Keywords: intracardiac echocardiography
papillary muscle-originating premature ventricular contractions
premature ventricular contractions
Lead sponsor: Shanghai Chest Hospital
Sponsor class: OTHER
Collaborators: name: The Second People's Hospital of Anhui Province
name: The First People's Hospital of Hefei
name: Qilu Hospital of Shandong University
name: Fujian Medical University Union Hospital
name: Chinese Academy of Medical Sciences, Fuwai Hospital
First posted: 2025-03-27
Enrollment: 156
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized, prospective, parallel, single-blind, multicenter clinical trial investigates the efficacy and safety of intracardiac echocardiography (ICE)-guided catheter ablation versus pressure-sensing catheter ablation alone in reducing PVC recurrence among patients with confirmed papillary muscle-originating premature ventricular contractions (PVCs). Participants were randomly allocated to either the ICE-guided intervention group or the conventional ablation control group following definitive diagnosis.


Eligibility criteria: Inclusion Criteria:

* Patients aged ≥18 years.
* Diagnosed with premature ventricular contractions (PVCs) originating from the papillary muscles.
* Symptoms refractory to antiarrhythmic drug therapy.
* Patients must be capable and willing to provide written informed consent for study participation.

Exclusion Criteria:

* History of cardiac surgery or any prior cardiac interventional procedures.
* Ischemic heart disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy.
* Severe hepatic or renal dysfunction:

AST/ALT \>3× upper limit of normal (ULN); Serum creatinine (SCr) \>3.5 mg/dl or creatinine clearance (Ccr) \<30 ml/min.

* Prior ablation for papillary muscle PVCs.
* Life expectancy \<1 year.
* Pregnancy or lactation.

Primary outcomes:
measure: Freedom from VC recurrence
timeFrame: Patients were followed up at 3 months postoperatively to assess recurrence.
Secondary outcomes:
measure: VC burden reduction
timeFrame: Patients were followed up at 3 months postoperatively to assess recurrence.
measure: Total procedure time
timeFrame: From the start to the end of the procedure.
measure: Total fluoroscopy time
timeFrame: From the start to the end of the procedure.
measure: Major perioperative complications
timeFrame: 30 days postoperatively.
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Chest Hospital
state: Xuhui
Study officials:
References:
Clinical trial NCT00734981: Efficacy Evaluation of a Novel Diagnostic Assay Which is the Basis for Seaforia Diagnostic System
Official title: Efficacy Evaluation of a Novel Diagnostic Assay Which is the Basis for Seaforia Diagnostic System
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Male Fertility
Lead sponsor: Lotus Bio Inc.
Sponsor class: OTHER
First posted: 2008-08-14
Enrollment: 60
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male volunteers

Brief summary: Evaluation of specificity and sensitivity of Seaforia- an vitro diagnostic system for evaluating semen quality.

Detailed description: Quantities assessment of semen quality as defined by:

Semen volume, semen pH, leukocytes concentration, sperm cells concentration, motile sperm cell concentration, total motile sperm cells threshold and sperm cells morphology

Eligibility criteria: Inclusion Criteria:

* Capable and willing to sign a consent form and participate in the study
* 20\<Age\<45
* Male

Exclusion Criteria:

None

Primary outcomes:
measure: Semen Quality as determined by the following parameters: Semen volume
timeFrame: The same day as sevan evaluation according to the gold standard
measure: Semen pH
timeFrame: The same day as sevan evaluation according to the gold standard
measure: Leukocytes concentration
timeFrame: The same day as sevan evaluation according to the gold standard
measure: Sperm cells concentration
timeFrame: The same day as sevan evaluation according to the gold standard
measure: Motile sperm cell concentration
timeFrame: The same day as sevan evaluation according to the gold standard
measure: Total motile sperm cells threshold
timeFrame: The same day as sevan evaluation according to the gold standard
measure: Sperm cells morphology
timeFrame: The same day as sevan evaluation according to the gold standard
Secondary outcomes:
Other outcomes:
Locations:
city: tel Aviv
country: Israel
facility: Assuta Medical Centers Ltd.
Study officials:
References: